🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

👇🏻

Intriguing discussion of OMICS behind the #HER2low breast cancer by @prat_aleix at #ESMO22 ✅Luminal A/B subtypes enriched in HER2Low vs HER2-0 ✅Small difference between HER2-0 and HER2Low in ERBB2 mRNA expression ✅New diagnostic assays (mRNA?) needed OncoAlert ESMO - Eur. Oncology

We can finally complete the table with all results (PFS and OS) from the CDK4/6 inhibitors phase III trials in HR+/HER2- MBC 👇🏽 OS in Paloma-2 was the only outcome did not meet significant difference 🪄🤨

The hardest #top10 (ish) I’ve ever done for a meeting: the amount of critical data that will be presented at #SABCS22 is impressive. Novel drugs, important trial updates, highly awaited biomarker data, new paradigms. Make sure not to miss what promises to be a remarkable SABCS!

#SABCS22 is about to start! So much data to be presented! Breast Cancer OncoAlert

Presenting today at #SABCS22 SABCS: Interim analysis of monarchE—phase 3 trial of #abemaciclib plus #endocrinetherapy for HR+ HER2- node+ high-risk early #breastcancer Read the Article in The Lancet Oncology: thelancet.com/journals/lanon…

What will we do Monday morning? My take home points from #SABCS22 - limiting and oversimplifying an incredible amount of high-quality research to fit in a few slides OncoAlert #bcsm SABCS

Salutiamo Gianluca Vialli con le parole che lui ha dedicato ai nostri ricercatori e alle nostre ricercatrici solo pochi mesi fa. Ci stringiamo alla sua famiglia in questo momento.

Nomen omen: lo studio BioItaLEE e la ricerca italiana su carcinoma mammario e biopsia liquida  tinyurl.com/2hdwycpu

I am happy to share the publication of the first results from the Phase IIIb Bioitalee trial, exploring the role of serum Thymidine Kinase activity in patients with metastatic breast cancer treated with Ribociclib and letrozole. Here the results: doi.org/10.1016/j.ejca… and 🧵

Life 2 Women - Il trattamento della paziente HR+ HER2- dall'adiuvante al metastatico. Domani 22 e 23 marzo, Napoli.📍 Con Board Scientifico Dott.ri Roberta Caputo, Carmine De Angelis, Mario Giuliano, Giuseppina Ricciardi, Maria Vita Sanò. Iscrizioni: overgroup.eu/evento/life-2-…

Just Out on The Oncologist Community In the Italian 🇮🇹DE_REAL Study: Trastuzumab deruxtecan (T-DXd) 💊demonstrated effective and safe outcomes in a real-world population of HER2+ 🧬metastatic #BreastCancer patients across various therapy lines ✅median real-world progression-free survival

Press release: the addition of pembro to neoadjuvant chemo improves OS in stage II-III TNBC. Tremendous news for one of the greatest unmet needs in breast oncology. Next step: tailoring strategies to preserve the benefit while minimizing IO-toxicities. merck.com/news/merck-ann…

Sacituzumab tirumotecan significantly and meaningfully improved PFS and OS in pretreated mTNBC. Another ADC improving outcomes in this setting! #ASCO24

DOMANI 5 e 6 luglio - Napoli Let’s talk about BReast CAncer Un incontro per valutare le opzioni terapeutiche per pazienti #mTNBC ed #eBC #HER2- con focus sulle mutazioni #BRCA. Resp. Scientifici Proff. Roberta Caputo e Carmine De Angelis. Iscrizioni: overgroup.eu/evento/lets-ta…

#AIOM24 | Il trattamento con T-DXd del mBC ricopre un ruolo sempre più importante in pratica clinica, anche in setting complicati, come quello della paziente con metastasi cerebrali. Quali sono i dati al riguardo? Il commento di Roberta Caputo tinyurl.com/5mynjnck

Prognostic implications of risk definitions from the monarchE and NATALEE trials academic.oup.com/jnci/advance-a… Study compared the prognostic impact of differing high-risk inclusion criteria used in the monarchE 🦋and NATALEE trials among patients with hormone

Second ADC Press Release of the day: the Trop2 ADC sacituzumab govitecan + pembro improved PFS vs. chemo + pembro for patients with untreated PD-L1+ mTNBC. New 1L standard of care coming. gilead.com/news/news-deta…

The Spotlight Program – FAD 2: Efficacia clinica di Sacituzumab Govitecan: prove a supporto dell’utilizzo in 2L #TNBC 📅 A partire da oggi 19 maggio e fino al 31 dicembre 2025, è attiva la FAD asincrona sull’efficacia clinica e il posizionamento terapeutico delle nuove opzioni